The company owned by UK-headquartered global investment firm Permira is now preparing for GMP qualification at the site, which also houses 150-liter glass and stainless-steel reactors that Cambrex said will continue to offer kilogram-scale manufacturing of materials for pre-clinical toxicological study applications.

The Tallinn complex provides custom organic synthesis and contract research, analytical and development services, working on process development and scale-up synthesis.

Cambrex also announced last month that it would expand its cGMP analytical testing capabilities in Longmont, Colorado, USA, doubling the footprint of its laboratory operations. The project includes the addition of chromatographic and dissolution equipment along with extra support equipment.

“This expansion of our Longmont facility is an example of the investments Cambrex is making to expand on our wide range of CDMO services. The strategic expansions to the cGMP testing area and addition of cutting-edge technologies enhances our stability programs and deepens the level of support we can deliver,” said Tracy Milburn, director of analytical services at Cambrex Longmont.

The Longmont facility became part of the Cambrex network through the acquisition of Avista Pharma Solutions in January 2019. The site provides support for small molecule drug products from discovery through to clinical scale and is fully integrated with direct technical transfer lines to Cambrex’s manufacturing sites in Charles City, Iowa; Whippany, New Jersey; and Mirabel in Quebec, Canada, for commercial-scale progression.

Author: Elaine Burridge, Freelance Journalist